TIANJIN, China – Among the country's plan to boost its biopharmaceutical sector, a focus on developing antibodies is likely to characterize the development of the industry over the next few years, said officials and executives during an annual gathering.
TIANJIN, China – Although the future of stem cell technology is bright, the sector in China has suffered due to a lack of clear regulations, with the then-Ministry of Health suspending clinical research and application of stem cell technology in 2011.
HONG KONG – A large Chinese conglomerate that rose to fame as a maker of the food additive monosodium glutamate, better known as MSG, has taken definitive steps into the biopharmaceutical space, sealing a deal to buying one of the major hepatitis B vaccine (HBV) suppliers in the country for ¥600 million (US$96 million).
TIANJIN, China – Although the future of stem cell technology is bright, the sector in China has suffered due to a lack of clear regulations, with the then-Ministry of Health suspending clinical research and application of stem cell technology in 2011.
TIANJIN, China – Among the country's plan to boost its biopharmaceutical sector, a focus on developing antibodies is likely to characterize the development of the industry over the next few years, said officials and executives during an annual gathering.
HONG KONG – Looking to reach out to more users and drug companies and riding the wave of growth of online information and platforms to facilitate the sharing of information between governments and users, China's drug regulator is now using mobile technology as part of its communications strategy.
HONG KONG – Looking to reach out to more users and drug companies and riding the wave of growth of online information and platforms to facilitate the sharing of information between governments and users, China's drug regulator is now using mobile technology as part of its communications strategy.
HONG KONG – A number of relatively young biopharma companies plan to issue shares on China's stock markets over the next few months, prompted by the lifting late last year of a ban on new issues.
HONG KONG – Despite all the talk of the bright future of China's biotech industry, the sector in this huge country remains in its infancy. Challenges in areas like funding and regulatory procedures have to be taken into account before stepping into the market, said investors at the Asia Biotech Invest conference.
HONG KONG – By 2017, the global pharmaceutical market will be worth $1.2 trillion and $250 billion will come from Asia. Those large sums of money should create multiple opportunities for investors that understand the nuances of the region, said industry insiders gathered here.
